Efficacy of sacral neuromodulation versus placebo in patients with multiple sclerosis with neurogenic lower urinary tract, bowel, and sexual dysfunction: study protocol for a multicenter randomized placebo-controlled trial
Abstract
Background: Multiple sclerosis (MS) is frequently accompanied by neurogenic lower urinary tract dysfunction (NLUTD). Sacral neuromodulation (SNM) is a guideline-endorsed therapy for refractory urinary symptoms, but evidence in NLUTD remains limited. We aim to provide robust efficacy data.
Methods: Since August 2023, this multicenter, placebo-controlled, double-blind, superiority, randomized trial has enrolled adults with MS and NLUTD refractory to guideline-endorsed therapies. All participants undergo a 1-month test phase with a tined lead and external stimulator, and responders (≥ 50% improvement in at least one group-specific bladder diary variable) receive an implantable pulse generator (IPG). After a 1-month optimization period, participants are randomized 1:1 to active (IPG ON) or placebo (IPG OFF) treatment for 4 months. Blinding is maintained through subsensory stimulation. Bladder diaries and questionnaires are collected at baseline, post-test phase, after optimization, midterm, and study end (total duration 6 months). Urodynamics are performed at baseline and at study end.
The primary objective is to determine whether continuous SNM is more effective than placebo in sustaining symptom improvement over time. The primary outcome is the proportion of participants with a confirmed response at randomization (C) who, 4 months after randomization (E), still show ≥ 50% improvement from baseline in at least one group-specific bladder diary variable. The proportions maintaining this response are compared between the IPG ON and IPG OFF groups.
Secondary outcomes include changes in bladder, bowel, and sexual function (ICIQ), health-related quality of life (EQ-5D-5L), treatment satisfaction (Global Assessment Score, GAS), urodynamic measures, safety monitoring, and effective stimulation parameters.
The primary outcome will be analyzed by logistic regression and continuous secondary outcomes by linear mixed models; subgroup analyses are exploratory. Assuming success rates of 0.5 (SNM) versus 0.15 (control), 27 patients per group are required (power 0.8, α = 0.05); 30 per group will be randomized (approximately 86 enrolled) to allow for dropouts.
Discussion: This trial will provide high-quality evidence on SNM in a well-defined MS cohort and may help refine patient selection and define the role of SNM in the management of lower urinary tract dysfunction.
Trial registration: ClinicalTrials.gov NCT05380856. Registered on 19 May 2022.
Related
- Accelerating tracheostomy decannulation with intermittent oro-esophageal feeding in neurogenic dysphagia: a multicenter randomized controlled trial.
- Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial
- Fecal microbiota transplantation for the treatment of neurogenic rosacea: protocol of a randomized, blinded, placebo-controlled explorer study.
- Efficacy and safety of Anas barbariae 200K in influenza-like illness: a randomized double-blind, placebo-controlled, multicenter study
- DIalysis Symptom COntrol-Pruritus Outcome Trial (DISCO-POT): A Multicenter Randomized Blinded Placebo Controlled Crossover Trial
BibTeX
@article{kobbero2026efficacy,
title = {{Efficacy of sacral neuromodulation versus placebo in patients with multiple sclerosis with neurogenic lower urinary tract, bowel, and sexual dysfunction: study protocol for a multicenter randomized placebo-controlled trial}},
author = {Hanne Kobberø and Jan Krhut and Peter Zvara and Mikkel Fode and Anna Mejldal and Helle Hvilsted Nielsen and Morten Blaaberg and Mads Hvid Poulsen},
journal = {Trials},
year = {2026},
month = nov,
doi = {10.1186/s13063-026-10068-z},
url = {https://link.springer.com/article/10.1186/s13063-026-10068-z},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Efficacy of sacral neuromodulation versus placebo in patients with multiple sclerosis with neurogenic lower urinary tract, bowel, and sexual dysfunction: study protocol for a multicenter randomized placebo-controlled trial
AU - Hanne Kobberø
AU - Jan Krhut
AU - Peter Zvara
AU - Mikkel Fode
AU - Anna Mejldal
AU - Helle Hvilsted Nielsen
AU - Morten Blaaberg
AU - Mads Hvid Poulsen
PY - 2026
DA - 2026/11/07
JO - Trials
DO - 10.1186/s13063-026-10068-z
UR - https://link.springer.com/article/10.1186/s13063-026-10068-z
AB - Background: Multiple sclerosis (MS) is frequently accompanied by neurogenic lower urinary tract dysfunction (NLUTD). Sacral neuromodulation (SNM) is a guideline-endorsed therapy for refractory urinary symptoms, but evidence in NLUTD remains limited. We aim to provide robust efficacy data. Methods: Since August 2023, this multicenter, placebo-controlled, double-blind, superiority, randomized trial has enrolled adults with MS and NLUTD refractory to guideline-endorsed therapies. All participants undergo a 1-month test phase with a tined lead and external stimulator, and responders (≥ 50% improvement in at least one group-specific bladder diary variable) receive an implantable pulse generator (IPG). After a 1-month optimization period, participants are randomized 1:1 to active (IPG ON) or placebo (IPG OFF) treatment for 4 months. Blinding is maintained through subsensory stimulation. Bladder diaries and questionnaires are collected at baseline, post-test phase, after optimization, midterm, and study end (total duration 6 months). Urodynamics are performed at baseline and at study end. The primary objective is to determine whether continuous SNM is more effective than placebo in sustaining symptom improvement over time. The primary outcome is the proportion of participants with a confirmed response at randomization (C) who, 4 months after randomization (E), still show ≥ 50% improvement from baseline in at least one group-specific bladder diary variable. The proportions maintaining this response are compared between the IPG ON and IPG OFF groups. Secondary outcomes include changes in bladder, bowel, and sexual function (ICIQ), health-related quality of life (EQ-5D-5L), treatment satisfaction (Global Assessment Score, GAS), urodynamic measures, safety monitoring, and effective stimulation parameters. The primary outcome will be analyzed by logistic regression and continuous secondary outcomes by linear mixed models; subgroup analyses are exploratory. Assuming success rates of 0.5 (SNM) versus 0.15 (control), 27 patients per group are required (power 0.8, α = 0.05); 30 per group will be randomized (approximately 86 enrolled) to allow for dropouts. Discussion: This trial will provide high-quality evidence on SNM in a well-defined MS cohort and may help refine patient selection and define the role of SNM in the management of lower urinary tract dysfunction. Trial registration: ClinicalTrials.gov NCT05380856. Registered on 19 May 2022.
SN - 1745-6215
ER -